"Safe Harbor" Statement under the U.S. Private Securities Litigation Reform Act of 1995; certain matters in this presentation, including forecasts of future demand and future Company performance, are forward-looking statements that are subject to risks and uncertainties that could cause actual results to materially differ, either better or worse, from those projected. Further discussions of risk factors are available in the Company's most recent SEC filings, including the annual report on Form 10-K for the fiscal year ended September 30, 2021 and any subsequent quarterly reports on Form 10-Q. The Company assumes no obligation to update the information in this presentation.
Regulation G
This presentation contains certain non-GAAP measures which are provided to assist in an understanding of the Azenta business and its operational performance. These measures should always be considered in conjunction with the appropriate GAAP measure. Reconciliations of all non-GAAP amounts to the relevant GAAP amount are provided as a separate presentation on the Company's website. All financial projections throughout this presentation, other than ROIC, exclude amortization of intangibles, restructuring expense and other special charges.
AGENDA
Building on Core Strengths. Forging New Growth Paths.
Azenta Life Sciences Overview
Market Drivers
Our Differentiated Solutions
Outlook: Compelling growth ahead
Azenta Life Sciences at a Glance
Azenta Products
$500M+ Business Growing Double Digits
Data shown is FY'21 as of 9/30/21 based on continuing operations *Non-GAAP financial measures - see reconciliation tables.
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Azenta Inc. published this content on 07 April 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 07 April 2022 16:32:02 UTC.
Azenta, Inc. is a provider of biological and chemical compound sample exploration and management solutions for the life sciences industry. The Companyâs segments include Sample Management Solutions, Multiomics and B Medical Systems. The Sample Management Solutions segment offers end-to-end sample management products and services, including sample and repository services and core products (automated stores, cryogenic systems, automated sample tube, and consumables and instruments). The Multiomics segment provides genomic and other sample analysis services, including gene sequencing and gene synthesis. B Medical Systems segment is focused on the manufacturing and distribution of temperature-controlled storage and transportation solutions in international markets to governments, health institutions, and non-government organizations. It provides products and services through its brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, Barkey, and B Medical Systems.
AZENTA, INC. 
